anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A technique for scheduling health care resources accesses performance data for any relevant resources required or desired for carrying out a procedure. The resources may include equipment, facilities, personnel, service providers, and so forth. The performance data may include indications of durations required for each of the resources for the particular type of procedure to be scheduled, as well as lead times for ordering resources, transit of the resources, and so forth. The information may further include preferences, such as patient and physician preferences that may affect the times required for the resources. Further information may include training or skill level of personnel, and so forth. Based on the information, one or more schedules for the required resources are updated, established, modified, or otherwise altered.
Sham Treatment. After 1 year, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
<P>PROBLEM TO BE SOLVED: To provide a method for generating an NPC1L1 polypeptide.  <P>SOLUTION: The human, rat and mouse NPC1L1 polypeptides and the polynucleotides encoding these polypeptides are provided. The method for detecting an agonist and antagonist to the NPC1L1 is also provided. An inhibitor of the NPC1L1 can be used for inhibiting the intestinal cholesterol absorption in a test subject. In one embodiment, a mouse which is a mutated transgenic mouse comprising the homozygous mutation of an endogeneous chromosomal NPC1L1 and not producing any functional NPC1L1 protein is provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC 50  values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.
People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high cholesterol, who are either taking medication for high cholesterol for 2 years or less; or have discussed managing high cholesterol in the past 2 years. These people will see items only pertaining to high cholesterol.
Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
Subjects with persistent colonies of MRSA/MSSA in the nostril will be recruited to receive either active treatment or placebo. This is a dose escalating study. First grout will receive either 1% Lytixar™ or placebo, next group 2% Lytixar™ or placebo and finally 5% Lytixar™ or placebo. Dose escalation will be performed after a brief safety evaluation of the tolerability after application of Lytixar™/placebo vehicle TID for three days. Pharmacokinetic samples will be collected from subjects who are willing. Subjects will be followed until 9 weeks after initiation of treatment.
Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
Adults

Dose Selection — Oral Olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mg initially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for Olanzapine would not be achieved for approximately 1 week in the typical patient. When dosage adjustments are necessary, dose increments/decrements of 5 mg QD are recommended. 

Efficacy in schizophrenia was demonstrated in a dose range of 10 to 15 mg/day in clinical trials. However, doses above 10 mg/day were not demonstrated to be more efficacious than the 10 mg/day dose. An increase to a dose greater than the target dose of 10 mg/day (i.e., to a dose of 15 mg/day or greater) is recommended only after clinical assessment. Olanzapine is not indicated for use in doses above 20 mg/day. 

Dosing in Special Populations — The recommended starting dose is 5 mg in patients who are debilitated, who have a predisposition to hypotensive reactions, who otherwise exhibit a combination of factors that may result in slower metabolism of olanzapine (e.g., nonsmoking female patients ≥65 years of age), or who may be more pharmacodynamically sensitive to olanzapine [see Warnings and Precautions (5.14), Drug Interactions (7), and Clinical Pharmacology (12.3)]. When indicated, dose escalation should be performed with caution in these patients. 

Maintenance Treatment — The effectiveness of oral Olanzapine, 10 mg/day to 20 mg/day, in maintaining treatment response in schizophrenic patients who had been stable on Olanzapine for approximately 8 weeks and were then followed for relapse has been demonstrated in a placebo-controlled trial [see Clinical Studies (14.1)]. The healthcare provider who elects to use Olanzapine for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. 

Adolescents

Dose Selection — Oral Olanzapine should be administered on a once-a-day schedule without regard to meals with a recommended starting dose of 2.5 or 5 mg, with a target dose of 10 mg/day. Efficacy in adolescents with schizophrenia was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials, with a mean modal dose of 12.5 mg/day (mean dose of 11.1 mg/day). When dosage adjustments are necessary, dose increments/decrements of 2.5 or 5 mg are recommended. 

The safety and effectiveness of doses above 20 mg/day have not been evaluated in clinical trials [see Clinical Studies (14.1)].

Maintenance Treatment — The efficacy of Olanzapine tablets for the maintenance treatment of schizophrenia in the adolescent population has not been systematically evaluated; however, maintenance efficacy can be extrapolated from adult data along with comparisons of olanzapine pharmacokinetic parameters in adult and adolescent patients. Thus, it is generally recommended that responding patients be continued beyond the acute response, but at the lowest dose needed to maintain remission. Patients should be periodically reassessed to determine the need for maintenance treatment.
OBJECTIVE: To investigate the roles and underlying mechanisms of vascular endothelial growth factor receptor-3 (VEGFR-3) in gastric cancer (GC).
METHODS: VEGFR-3 gene expression profiles in human gastric adenocarcinoma (GAC) tissues were analysed using The Cancer Genome Atlas database. Human GC cell lines and were used for in vitro studies. Mouse models of GC and distant metastasis were used for in vivo studies. Silencing of VEGFR-3 gene expression was achieved using small interfering RNA.
RESULTS: VEGFR-3 gene expression was significantly elevated in GAC tissues and GC cells. Higher VEGFR-3 expression was positively correlated with more advanced stages and a greater number of metastatic lymph nodes. In vitro studies in GC cells showed that knockdown of VEGFR-3 gene expression significantly suppressed cell proliferation and migration, but promoted apoptosis. In vivo investigations revealed that silencing of VEGFR-3 gene expression exhibited significant inhibition on tumour growth and metastasis. Further mechanistic studies showed that VEGFR-3 exerted its pathological roles by affecting the key molecules in the apoptotic and epithelial-mesenchymal transition pathways.
CONCLUSION: The molecular pathways associated with VEGFR-3-mediated pathological effects could be targets in the development of novel approaches for the diagnosis, prognosis and treatment of GC.
The invention belongs to the technical field of preparation of medical materials, and particularly relates to an artesunate-loaded coordination metal organic framework nano preparation as well as a preparation method and application thereof. According to the invention, zinc nitrate hexahydrate, 2-methylimidazole and artesunate are used as precursors, and artesunate is loaded in a metal coordination mode to synthesize the artesunate-loaded hybrid zeolite imidazole ester skeleton nanomaterial Art-ZIF NPs. The size is nano-scale, and the water dispersibility is good, and the loading rate and the loading quantity are high. The sustained release tablet has the characteristic of acid-responsive degradation, can be stable under physiological conditions, but disintegrates under acidic conditions (PH < 5.5), thereby realizing intelligent controlled release of the drug. The invention fully overcomes the defect of poor water solubility of artesunate, and has remarkable inhibition effect on the growth of tumor cells. The preparation process is simple, the operation is simple, and the reaction condition is mild; the method has low instrument requirement, and the experimental process is environment-friendly and can be applied to large-scale industrial production.
PURPOSE: A pharmaceutical composition containing Ecklonia cava-derived phloroglucinol derivative is provided to suppress HIV-1(human immunodeficiency virus type-1) causing cell fusion without cytotoxicity. CONSTITUTION: A pharmaceutical composition for anti-HIV-1 suppression contains Ecklonia cava extract as an active ingredient. The Ecklonia cava extract is an ethanol extract. A pharmaceutical composition for anti-HIV-1 suppression contains Ecklonia cava-derived phloroglucinol derivative as an active ingredient. The phloroglucinol derivative is 6,6'-bieckol of chemical formula 1. The pharmaceutical composition further contains a carrier, excipient, and diluents. A health food for anti-HIV-1 suppression contains the Ecklonia cava-derived phloroglucinol derivative as an active ingredient. The health food is used in the form of tablet, capsule, powder, granule, liquid, or pill.
A computer implementable system manages genetic information associated with a human genome of a target subject and displayed via a graphical user interface (GUI). The target subject genetic information is encrypted. The system compares the clinical data of the target subject with clinical data in its database to provide a first ranking of possible genetic diseases. Then the genetic information of the target subject is compared to the genetic information in the database to re-rank via a weight score evaluation based on predetermined criteria thereby providing a second ranking of possible genetic diseases. Allowing a user to decrypt a portion or portions of the encrypted target subject genome that are related to the possible genetic diseases and blocking decryption of the rest of the genome. Providing access to the decrypted portions of the target subject genome via the GUI.
The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. IBRANCE should be taken with food [see Clinical Pharmacology (12.3)].

Administer the recommended dose of an aromatase inhibitor when given with IBRANCE. Please refer to the Full Prescribing Information for the aromatase inhibitor being used.

When given with IBRANCE, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant.

Patients should be encouraged to take their dose of IBRANCE at approximately the same time each day.

If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time. IBRANCE capsules should be swallowed whole (do not chew, crush, or open them prior to swallowing). Capsules should not be ingested if they are broken, cracked, or otherwise not intact.

Pre/perimenopausal women treated with the combination IBRANCE plus an aromatase inhibitor or fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.

For men treated with combination IBRANCE plus aromatase inhibitor therapy, consider treatment with an LHRH agonist according to current clinical practice standards.
Childhood maltreatment (CM) leads to a lifelong susceptibility to mental ill-health which might be reflected by its effects on adult brain structure, perhaps indirectly mediated by its effects on adult metabolic, immune, and psychosocial systems. Indexing these systemic factors via body mass index (BMI), C-reactive protein (CRP), and rates of adult trauma (AT), respectively, we tested three hypotheses: (H1) CM has direct or indirect effects on adult trauma, BMI, and CRP; (H2) adult trauma, BMI, and CRP are all independently related to adult brain structure; and (H3) childhood maltreatment has indirect effects on adult brain structure mediated in parallel by BMI, CRP, and AT. Using path analysis and data from N = 116,887 participants in UK Biobank, we find that CM is related to greater BMI and AT levels, and that these two variables mediate CM's effects on CRP [H1]. Regression analyses on the UKB MRI subsample (N = 21,738) revealed that greater CRP and BMI were both independently related to a spatially convergent pattern of cortical effects (Spearman's ρ = 0.87) characterized by fronto-occipital increases and temporo-parietal reductions in thickness. Subcortically, BMI was associated with greater volume, AT with lower volume and CPR with effects in both directions [H2]. Finally, path models indicated that CM has indirect effects in a subset of brain regions mediated through its direct effects on BMI and AT and indirect effects on CRP [H3]. Results provide evidence that childhood maltreatment can influence brain structure decades after exposure by increasing individual risk toward adult trauma, obesity, and inflammation.
The retrospective arm of the study will include 200 patients meeting the inclusion criteria who have received a cardiac CT from January 2013 to date of approval amendment. (2013 was chosen as starting year to retrieve CT and clinical date in order to have at least 5 years of follow-up per patients).
We examined the sensitivity and time-course of recovery of neuromuscular and perceptual player monitoring measures to U-18 English Premier League academy football match play. Eighteen players performed maximal posterior chain, hip adductor and abductor isometric strength tests, countermovement jumps (CMJ) and provided self-report wellbeing scores around eight competitive league home games: 1 day before (MD-1), pre-match (MD-PRE), post-match (MD-POST) and two (MD+2) and three (MD+3) days post-match. A permutational multivariate analysis of variance and post hoc univariate analyses of variance were used to examine match-induced responses to monitoring variables. Between MD-1 and MD-POST, we observed small to moderate reductions to the adductor and abductor peak force and maximal impulse and IPCS peak force; small reductions to CMJ jump height (JH) (flight time), eccentric peak force and eccentric deceleration rate of force development and moderate to large reductions to perceived fatigue, muscle soreness and mood. No match-induced changes were observed for CMJ flight time: contraction time or eccentric duration. Posterior chain, abductor, CMJ and self-report measures normalised by MD+3 but adductor peak force remained compromised at MD+3 (ES = small). Posterior chain, adductor and abductor peak isometric force and maximal impulse; CMJ JH, eccentric peak force and eccentric deceleration rate of force development and perceived fatigue, muscle soreness and mood are sensitive to match-induced fatigue. Since adductor peak force remained compromised at MD+3, it is apparent that players might not achieve complete neuromuscular recovery within 3 days of match play, and that the adductor muscle group might be particularly vulnerable to match-induced fatigue.
PURPOSE: A multi-portion intra-oral dosage form with oranoleptic properties having a pharmaceutically active agent or health promoter is provided to ensure drug compliance and efficiency. CONSTITUTION: A multi-portion intra-oral dosage form contains a pharmaceutically active agent or health promoter. Two or more portions have distinguishable difference in organoleptic sensation. The organoleptic sensation includes scent change. The each portion is pharmaceutically active agent, pH-buffer, pH-controlling ingredient blocking ingredient, color ingredient, adhesive ingredient, health promoter, tooth whitening agent, breath freshener or anti-dental caries. A method for transferring nicotine, randomly different smoking quitting agent or nicotine-mimic comprises: a step of administering the multi-portion intra-oral dosage form to oral cavity of a subject; and a step of release nicotine, randomly different smoking quitting agent or nicotine-mimic from the oral cavity to saliva to absorb to the whole body circulatory system of the subject.
PURPOSE:To provide the titled pressure-sensitive adhesive containing polymaltotriose, carboxymethylcellulose and a water-retaining softening agent, having high adhesivity to oral mucosa and peel resistance, free from dissolution and disintegration with saliva and capable of being stably retained on the mucosa. CONSTITUTION:The objective agent can be produced by compound (A) a polymaltotriose having a chemical structure characterized by maltotriose units linked with each other essentially through alpha-1,6 bonds, (B) a carboxymethylcellulose having anetherification degree of 0.6-1.8 and/or its salt and (C) a water-retaining softening agent compatible with the component A and B (e.g. glycerol, diglycerol, triglycerol, maltitol, etc.). The weight ratio of A:B is 95:5-60:40 and the amount of the component C is 40-600pts.wt. per 100pts.wt. of A+B. The agent is used for the protection of the wound of oral mucosa, fixing of a drug for oral cavity administration to the mucosa of oral cavity, etc. Furthermore, it can be used as a topical remedy by adding a drug to the adhesive and applying to the oral mucosa.
Patients undergo collection of medical information about COVID-19 symptoms, treatments/cancer treatments and outcomes, and results from laboratory tests and imaging scans performed as part of routine care for up to 2 years. Patients also undergo collection of blood samples at the same times they receive routine bloodwork up to 8 times for adults and up to 5 times for children. Patients who are hospitalized for COVID-19 undergo collection of blood samples at up to 6 additional times for adults and up to 3 additional times for children. Adult patients also complete quality of life questionnaire.
A medical device ( 10 ) includes a structure ( 12 ) adapted for introduction into a patient, the structure ( 12 ) being formed of a preferably non-porous base material ( 14 ) having a roughened or textured surface ( 16 ). The structure ( 12 ) is conveniently configured as a vascular stent with a base material ( 14 ) of stainless steel, nitinol or another suitable material. The medical device ( 10 ) also includes a layer ( 18 ) of a bioactive material posited directly upon the roughened or textured surface ( 16 ) of the base material ( 14 ) of the structure ( 12 ). The surface ( 16 ) of the base material ( 14 ) is roughened or textured by etching or by abrasion with sodium bicarbonate or another suitable grit. A preferred roughened or textured surface ( 16 ) is thought to have a mean surface roughness of about 10 muin. (about 250 nm) and a surface roughness range between about 1 muin. and about 100 muin. (about 25 nm and about 2.5 mum). The particularly preferred use of sodium bicarbonate as the abrasive to provide roughness or texture to the surface ( 16 ) of the base material ( 14 ) of the structure ( 12 ) is additionally advantageous in the low toxicity of the sodium bicarbonate to production workers, the ease of product and waste cleanup, and the biocompatibility of any residual sodium bicarbonate.
FIELD: medicine. SUBSTANCE: method involves introducing labeled antibodies or labeled alpha-fetoprotein into biological patient sample to enable labeled antibodies or labeled alpha-fetoprotein to enter into reaction with alpha-protein receptor in the biological sample. Binding alpha-protein receptor sides are determined in the biological material at the next stage having entered into reaction with labeled antibodies or alpha-protein for detecting cancer. It is advantageous to examine the biological patient sample before the introduction stage. One stage of the method is alpha-fetoprotein receptor antibody introduction into the patient cells affected with cancer. Then, the stage of reaction of alpha-fetoprotein receptor antibodies to alpha-fetoprotein receptor of the patient cells affected with cancer follows for inhibiting growth of the cells affected with cancer or necrosis of the cells affected with cancer. Method of patient observation and cancer treatment is also described. Then, a test stage follows. The tests are performed in predefined moments of time after treatment for determining alpha- fetoprotein receptor sizes. EFFECT: enhanced effectiveness of diagnosis and treatment method. 24 cl, 10 dwg, 1 tbl
Exposure to cat allergen in the presence of active air cleaners then placebo. 3-week wash-out period between the two exposures.
PTNS therapy is performed as follows; patient is asked to sit with legs slightly bent. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial surface of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage electrical stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and the subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.